Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,083 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. von Groote-Bidlingmaier F, et al. Among authors: wells c. Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7. Lancet Respir Med. 2019. PMID: 30630778 Clinical Trial.
Delamanid for Extensively Drug-Resistant Tuberculosis.
Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. Gupta R, et al. N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. N Engl J Med. 2015. PMID: 26176402 Free article. Clinical Trial. No abstract available.
Pan-tuberculosis regimens: re-framing the argument.
Gupta R, Wells CD. Gupta R, et al. Lancet Respir Med. 2018 Jul;6(7):e28. doi: 10.1016/S2213-2600(18)30189-9. Lancet Respir Med. 2018. PMID: 29976444 No abstract available.
Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Gupta R, et al. Among authors: wells cd. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Int J Tuberc Lung Dis. 2016. PMID: 28240570 Review.
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Mallikaarjun S, Wells C, Petersen C, Paccaly A, Shoaf SE, Patil S, Geiter L. Mallikaarjun S, et al. Among authors: wells c. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85. doi: 10.1128/AAC.00509-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27458223 Free PMC article. Clinical Trial.
Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Gler MT, et al. N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433. N Engl J Med. 2012. PMID: 22670901 Free article. Clinical Trial.
2,083 results